We serve Chemical Name:sodium hexadecanoate-d31 CAS:467235-83-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:sodium hexadecanoate-d31
CAS.NO:467235-83-2
Synonyms:sodium hexadecanoate-d31
Molecular Formula:C16D31NaO2
Molecular Weight:309.59700
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:40.13000
Exact Mass:309.41700
LogP:4.21760
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like sodium hexadecanoate-d31 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,sodium hexadecanoate-d31 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,sodium hexadecanoate-d31 Use and application,sodium hexadecanoate-d31 technical grade,usp/ep/jp grade.
Related News: The pivotal TULIP (Treatment of Uncontrolled Lupus via the Interferon Pathway) phase III programme includes two trials, TULIP-1 and TULIP-2, that evaluated the efficacy and safety of anifrolumab versus placebo. Benzenamine, 2-(1H-1,2,4-triazol-1-yl)- manufacturers SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 3-hydroxy-5-(4-isopropylphenyl)-1-phenyl-4-(thiophene-2-carbonyl)-1,5-dihydro-2H-pyrrol-2-one suppliers The client needed full development and product readiness with an extremely short supply of the API. In addition, the scale-up batch was small because of the low volume of product demands of their orphan drug. dimethyl (2R,7R)-2,7-diacetamido-2,7-di(but-3-enyl)oct-4-ynedioate vendor & factory.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 3-hydroxy-5-(4-isopropylphenyl)-1-phenyl-4-(thiophene-2-carbonyl)-1,5-dihydro-2H-pyrrol-2-one suppliers The client needed full development and product readiness with an extremely short supply of the API. In addition, the scale-up batch was small because of the low volume of product demands of their orphan drug. dimethyl (2R,7R)-2,7-diacetamido-2,7-di(but-3-enyl)oct-4-ynedioate vendor & factory.
